U2 small nuclear RNA contains 13 pseudouridine (I) nucleotides, of which 11 are clustered in 5' regions involved in base-pairing interactions with other RNAs in the spliceosome. As a first step toward understanding the J formation pathway in U2 RNA, we investigated I formation on unmodified human U2 RNA in a HeLa cell extract system. I formation was found to occur specifically within only those RNase Ti oligonucleotide fragments of U2 RNA known to contain I in vivo. Using 5-fluorouridine (FUrd)-containing U2 RNAs as specific inhibitors of ' formation in non-FUrdsubstituted substrate U2 RNA, we found that wild-type FUrdcontaining U2 RNA as well as several FUrd-containing mutant U2 RNAs completely inhibited 'I formation. In contrast, certain other mutant U2 RNAs containing FUrd displayed reduced inhibitory capacity. In these cases I modifications occurred in specific RNase Ti fragments of the substrate U2 RNA only if the FUrd-containing competitor RNA was mutated at or near this site. Formation of I at one site in U2 RNA appeared to be neither dependent on prior 'I formation at another site or sites nor required for subsequent I formation elsewhere in the molecule. This autonomous mode of I formation may be driven by multiple I synthase enzymes acting independently at different sites in U2 RNA.
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At least five small nuclear RNAs (snRNAs)-U1, U2, U4, U5, and U6-participate in the splicing of pre-mRNA (1, 2) . The synthesis of the spliceosomal snRNAs themselves has turned out to be more complex than might have been anticipated, including a cytoplasmic phase of U1, U2, U4, and U5 3' end processing, 5 ' cap hypermethylation, and small nuclear ribonucleoprotein (snRNP) assembly (3) .
One of the more enigmatic posttranscriptional modifications of the snRNAs is pseudouridine (T) formation. In the course ofdeveloping an in vitro assembly system for snRNPs, we observed that T formation occurred (4, 5) , and subsequent studies demonstrated that T formation takes place at specific sites in U1, U2, and U5 RNAs in this in vitro system (6, 7) . Additional experiments with 5-fluorouridine (FUrd)-substituted snRNAs as inhibitors of T formation in the homologous 32P-labeled snRNA substrate revealed that there are multiple snRNA T synthase activities in HeLa cell extracts with distinct specificities for U1, U2, or U5 RNAs (7) . For example, FUrd-containing U2 RNA inhibits T formation in 32P-labeled U2 RNA but not in 32P-labeled U1 or U5 RNA (7) .
Mammalian U2 RNA contains 13 T nucleotides, the most -of any of the known spliceosomal snRNAs (8) . We have examined the site specificity of U2 RNA T formation in vitro and have asked whether T formation throughout U2 RNA proceeds via a pathway of obligatorily sequential reactions or independently at the various sites.
MATERIALS AND METHODS
RNA Transcription and in Vitro Assembly. The plasmids encoding recombinant U2 RNA have been described (9) . Wild-type (wt) U2 RNA was transcribed in vitro from Sma I-digested plasmid pMRG3U2-27 with T7 RNA polymerase (9) . Mutant U2 RNAs (Table 1) (10) before use in the AI formation assays.
I Formation Reactions. The in vitro system for T formation is adapted from the snRNP assembly system (4, 5) . A typical 100-,4 reaction mixture contained =5 ng of gelpurified U2 RNA, 60% (vol/vol) HeLa cell cytoplasmic S100 extract (11) , ATP (0.5 mM), creatine phosphate (20 mM), and MgCl2 (3.2 mM). Inhibition of U2 RNA T modification by FUrd-containing RNAs was examined by preincubating the FUrd-containing inhibitor RNA (25 ng/100 pu, constituting a 5-fold molar excess over the U2 RNA substrate; ref. 7) in the reaction mixture at 370C for 10 min prior to addition of the substrate RNA (either 3H-or 32P-labeled wt U2 RNA). The amount of competitor RNA necessary for maximal inhibition was determined as described (7). The reaction mixture was then incubated for an additional 60 min at 370C, unless otherwise indicated. In some cases, assembled U2 snRNPs were immunoselected from the reaction mixture (10) . Extraction of total RNA, electrophoresis of RNA in polyacrylamide/urea gels, visualization of RNA by autoradiography, and elution of RNA from gels have been described (4) (5) (6) (7) 10) .
Assays of I Formation. The two assays of't formation used in this study have been described (6) . In the first, the 3H at pyrimidine C-5 of [3H]UTP-labeled U2 RNA is exchanged with the bulk solvent when uridine is converted to T (12 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. mixed with an aqueous-based scintillation fluid and the amount of 3H released was determined. The second assay involved [32P]UTP-labeled U2 RNA. After incubation in the reaction mixture (with or without FUrd-containing inhibitor RNA) the 32P-labeled U2 RNA was phenol/chloroform extracted, gel purified, and then digested with RNase T1 (Pharmacia) (6) . The digestion products were electrophoresed in a 20%o polyacrylamide/8.3 M urea gel and identified by autoradiography. The RNase T1 fragments were eluted from the gel and digested with nuclease P1 (100 pg/ml) in 20 mM sodium acetate (pH 5. 
RESULTS
It is a posttranscriptionally modified form of uridine present in a variety of RNA molecules including snRNAs, tRNAs, and rRNAs (for reviews see refs. 8, 14, and 15). T synthases catalyze an isomerization involving cleavage of the uracil N-glycosidic bond and formation of a C-glycosidic bond at C-5. FUrd-substituted RNAs are potent and specific inhibitors of T formation in homologous unsubstituted tRNAs (16, 17) and snRNAs (7). We used FUrd-substituted wt and mutant U2 RNAs (Table 1) as specific inhibitors to study T formation in U2 RNA, which is the most highly modified of the snRNAs, containing 13 (12) . (This is an indirect assay ofT formation, useful for screening large numbers of reactions.) As expected, when FUrdsubstituted U2 RNA, a specific inhibitor of%I formation in U2 RNA (7), was included in the reaction mixture, an inhibition of 3H release from 3H-labeled U2 RNA was observed (averaging 28% of control, Table 2 ). We next examined the capacity of various FUrd-substituted mutant U2 RNAs to act as specific inhibitors of IV formation ( Table 2 ). The majority of the FUrd mutant U2 RNAs inhibited 3H release from the U2 RNA substrate to extents similar to that observed for FUrd-substituted wt U2 RNA. These "no-effect" mutations include both single nucleotide replacements (e.g., mutants 3 and 11) and large deletions (e.g., mutants 7, 36, and 37), indicating that there are discrete regions of U2 RNA that do not play a role in directing T formation. In (8) with the residues boxed. The RNase T1 oligonucleotides that were analyzed for T content (see Table 3 ) are identified by solid lines. (Table  1) . This suggests that the sequences and/or structures in the 3' half of U2 RNA (nt 105-188, a region which does not include any of the I positions) are not sufficient for inhibition of T formation.
We examined the possibility that the intermediate or lack of inhibition of T formation observed with some of the FUrd mutant U2 RNAs might be due to their different stabilities in the in vitro system. RNAs were transcribed in the presence of [a-32P]GTP and 5-fluoro-UTP, gel purified, and incubated in the in vitro system at the same concentrations used in the 3H-release assays. After phenol/chloroform extraction and ethanol precipitation, the 32P-labeled, FUrd-substituted RNAs were electrophoresed in a 10%o polyacrylamide/8.3 M urea gel and examined by autoradiography. Little if any degradation was observed even after 60 min of incubation (Fig. 2) . As another indication of their integrity, we found that all of the FUrd mutant RNAs, with the exception ofmutants 4, 50, and 52, were readily assembled into snRNP complexes, as defined by their ability to be immunoselected by Sm monoclonal data not shown) . Thus, the intermediate or lack ofinhibition of3H release observed for some ofthe FUrd mutant RNAs can be attributed to their inherent differing capacities to act as specific inhibitors of T formation.
Specific Inhibition of t Formation in U2 RNA by FUrdSubstituted RNAs. Most of the FUrd RNAs which only partially inhibited T formation are mutated in a location at or near a site of T modification. We therefore wanted to directly examine T formation in U2 RNA. [a-32P]UTP-labeled wt U2 RNA was incubated in the in vitro system and FUrd RNAs were included as indicated. The assembled snRNP particles were immunoselected with Sm antibody and the RNAs were isolated and digested with nuclease P1 before TLC and autoradiography. The antibody selection was employed to remove assembled U2 particles from degraded 32P-labeled U2 RNA fragments that might interfere with the assay. A prominent T spot (comprising 10-15% of the theoretical 100% level of T formation) was observed when no FUrdsubstituted RNA was included in the reaction mixture (Fig.  3, lane tRNA) , in keeping with previous results (7). However, when FUrd-substituted wt U2 RNA was included, IV formation was almost completely inhibited, again demonstrating that FUrd-substituted wt U2 RNA is a potent inhibitor of 'I formation in U2 RNA. These data also suggest that the lack of complete inhibition observed in Table 2 (3H-release assay) when FUrd wt U2 RNA was used as an inhibitor could be due to other reactions involving the C-5 tritium atom that occur in the 3H-release assay.
When various FUrd mutant U2 RNAs were examined as specific inhibitors ofT formation in the substrate RNA (Fig. 3) , results similar to those obtained by the 3H-release assay were observed. FUrd (Fig. 3) .
It is possible that those mutants which cause only partial inhibition interact less efficiently with the activity responsible for 4I formation in U2 RNA, resulting in a general reduction in the overall amount of4l formation. It is also possible that if the mutation in a FUrd inhibitor RNA were located at or near a site of T modification, it would not be capable of inhibiting T formation at the corresponding site in the substrate RNA. To examine these possibilities, high-specific-activity [ Fig. 1 ), but of the substrate RNA ( Table 3 ), suggesting that the presence of e would not contain label derived from a uridine residue at position 58 in the FUrd RNA is important tNase T1 digestion produces 3' phosphates for specific inhibition of I formation in this region of U2 RNA. Ives 5' phosphates.} In contrast, the mutation A90 -+ U had no affect on the ability l-substituted RNA was included in the of FUrd 12 RNA to specifically inhibit T formation at positions ' was present in all of the expected RNase 89 and 91 (which are in the 15-mer T1 oligonucleotide of the es (Table 3) . Moreover, when FUrdsubstrate RNA).
RNA was included as an inhibitor, none of substrate RNA (the region mutated in When FUrd mutant 22 RNA (CCUGG -* GGACC at nt ble 1), whereas complete inhibition was 154-158; a stem IV mutant) was included in the reaction as an her T1 fragments.
inhibitor, T formation was observed in the 6-mer T1 oligonucleotide of the substrate RNA. Since the mutation in this FUrd Tf P in 32P-labeled wt U2 RNA after RNA is in the fourth stem-loop it is not readily apparent why 1-containing U2 RNAs there was incomplete inhibition of T formation in the 6-mer. Presence of ' in RNase T1 fiagments* This mutant would be expected to exhibit wt inhibition, but it does not in either this assay or the 3H-release assay (Table 2) . L5-mer 1i-mer 10 As mentioned earlier, several posttranscriptional modifications of U1, U2, U4, and U5 snRNAs take place in the cytoplasm before the mature snRNA returns to the nucleus as a functional snRNP (3). These include both covalent modifications such as 5' cap hypermethylation, 3' end processing, and l formation, as well as the association ofthese RNAs with both common and specific sets of proteins (1). Since both trimethylguanosine and snRNP protein antibodies immunoselect precursor forms of U1, U2, U4, and U5 snRNAs from HeLa cytoplasmic extracts (18) (19) (20) , it is clear that both 5' cap hypermethylation and snRNP assembly precede 3' end processing. However, it is not known where I formation fits into this sequence of events. In the in vitro system employed in the present investigation, I formation in U5 RNA was dependent on binding ofthe Sm snRNP proteins (6 (23) (24) (25) and FUrdsubstituted U2 RNA assembles into altered snRNP particles (26) . Our present findings suggest that inhibition of l formation in the spliceosomal snRNAs may be among the factors in the observed inhibition of pre-mRNA splicing in 5-fluorouraciltreated cells (23) (24) (25) . In the case of U2 RNA, several of the ' nucleotides are located in regions known to interact either with pre-mRNA (U2 nt 33-38) or with U6 RNA (U2 nt [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Similarly, the two I nucleotides in U1 RNA are located in a region that interacts with pre-mRNA. While the precise role of ' in snRNAs is not known, the C-S glycoside configuration is thought to increase the hydrogen-bonding potential ofthe uracil ring. For example, poly(A)poly(I) duplexes are more stable than poly(A)-poly(U) duplexes (27) . I can form hydrogen bonds to bridging water molecules or to vicinal ribose 2'-hydroxyl groups (28) . Inhibition of a I-based repertoire of hydrogen bonding in snRNAs, presumably essential for their role in mRNA splicing, may be among the factors at play when cells or patients are treated with 5-fluorouracil.
